Synergy Pharmaceuticals Inc. (NASDAQ:SGYP)’s share price was down 3.3% on Wednesday . The stock traded as low as $4.55 and last traded at $4.70, with a volume of 2,479,358 shares changing hands. The stock had previously closed at $4.86.

Several brokerages recently commented on SGYP. BTIG Research reissued a “buy” rating and issued a $11.00 price target on shares of Synergy Pharmaceuticals in a research note on Tuesday, April 19th. Roth Capital reissued a “buy” rating and issued a $6.50 price target on shares of Synergy Pharmaceuticals in a research note on Tuesday, April 19th. Rodman & Renshaw reissued a “buy” rating and issued a $16.00 price target on shares of Synergy Pharmaceuticals in a research note on Thursday, April 21st. Zacks Investment Research raised Synergy Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.00 price target for the company in a research note on Monday, May 16th. Finally, Canaccord Genuity reissued a “buy” rating and issued a $13.00 price target on shares of Synergy Pharmaceuticals in a research note on Monday, May 23rd. Two investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $10.37.

The company’s market capitalization is $830.84 million. The stock has a 50 day moving average price of $3.97 and a 200 day moving average price of $3.53.

Synergy Pharmaceuticals (NASDAQ:SGYP) last released its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.23) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.20) by $0.03. Equities analysts forecast that Synergy Pharmaceuticals Inc. will post ($1.03) EPS for the current fiscal year.

Synergy Pharmaceuticals Inc (Synergy) is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The Company’s GI platform includes two lead product candidates: plecanatide and dolcanatide. It is engaged in the discovery, research and development involving uroguanylin analogs for the treatment of functional GI disorders and inflammatory bowel disease.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.